{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Several LRRK2 variants associated with PD exhibit increased kinase activity suggesting a gain-of-function mechanism, in which elevated kinase activity of LRRK2 triggers neurotoxicity and neurodegeneration (Smith et al. 2006; West et al. 2007).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism for LRRK2 variants as a gain-of-function due to increased kinase activity leading to neurotoxicity and neurodegeneration, which is relevant to Parkinson disease (PD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "By in vitro kinase assays we found that different MAPKKs, MKK3/6 and MKK4/7, are phosphorylated by LRRK2. PD-associated LRRK2 variants having mutations within their kinase domain display a higher degree of activity towards MKK phosphorylation.",
          "judgment": "Yes",
          "reasoning": "The in vitro kinase assays used in the study effectively model the disease mechanism by measuring increased kinase activity of LRRK2 variants on MAPKK substrates, which reflects the gain-of-function mechanism implicated in PD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The kinase dead variant of LRRK2, LRRK2 K1906M, served as a negative control and showed no MKK3/6 phosphorylation... For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant and differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA).",
          "judgment": "Yes",
          "reasoning": "The paper includes a negative control (kinase dead LRRK2 K1906M) and wild-type LRRK2 as a normal control. It also explicitly states the use of at least four independent data points (replicates) per mutant, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Next, we compared the kinase activity of wild-type LRRK2 to the disease-associated variants LRRK2 R1441C, mutated within its GTPase domain Roc, LRRK2 G2019S and LRRK2 I2020T.",
          "judgment": "Yes",
          "reasoning": "The study includes known pathogenic variants (LRRK2 G2019S, I2020T, R1441C) as controls in the kinase activity assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The kinase activity of LRRK2 G2019S is increased to about 3-4-fold compared with wild-type LRRK2... differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA). Pair-wise comparison was performed by Tukey's post-hoc test.",
          "judgment": "Yes",
          "reasoning": "The paper provides statistical analyses (ANOVA and Tukey's post-hoc test) to compare phosphorylation levels between wild-type and mutant LRRK2, and quantifies the fold increase in activity for G2019S, which is sufficient to infer OddsPath or effect size.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "The LRRK2 G2019S mutant shows a 3-4-fold higher phosphorylation of MKK6 compared with wild-type LRRK2.",
          "judgment": "PS3_moderate",
          "reasoning": "Although a direct OddsPath value is not provided, the 3-4-fold increase in kinase activity for G2019S compared to wild-type suggests a moderate level of pathogenic evidence based on ACMG thresholds (OddsPath > 4.3 for moderate). Therefore, the evidence strength is rated as PS3_moderate.",
          "next_step_or_outcome": "Final evidence strength determination"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S is rated as PS3_moderate due to a significant 3-4-fold increase in kinase activity compared to wild-type, supported by robust in vitro kinase assays with appropriate controls and statistical analyses, aligning with a gain-of-function mechanism for Parkinson disease."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Several LRRK2 variants associated with PD exhibit increased kinase activity suggesting a gain-of-function mechanism, in which elevated kinase activity of LRRK2 triggers neurotoxicity and neurodegeneration (Smith et al. 2006; West et al. 2007).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism for LRRK2 variants as a gain-of-function due to increased kinase activity leading to neurotoxicity and neurodegeneration, relevant to Parkinson disease (PD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "By in vitro kinase assays we found that different MAPKKs, MKK3/6 and MKK4/7, are phosphorylated by LRRK2. PD-associated LRRK2 variants having mutations within their kinase domain display a higher degree of activity towards MKK phosphorylation.",
          "judgment": "Yes",
          "reasoning": "The in vitro kinase assays used in the study effectively model the disease mechanism by measuring increased kinase activity of LRRK2 variants on MAPKK substrates, reflecting the gain-of-function mechanism implicated in PD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The kinase dead variant of LRRK2, LRRK2 K1906M, served as a negative control and showed no MKK3/6 phosphorylation... For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant and differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA).",
          "judgment": "Yes",
          "reasoning": "The paper includes a negative control (kinase dead LRRK2 K1906M) and wild-type LRRK2 as a normal control. It also explicitly states the use of at least four independent data points (replicates) per mutant, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Next, we compared the kinase activity of wild-type LRRK2 to the disease-associated variants LRRK2 R1441C, mutated within its GTPase domain Roc, LRRK2 G2019S and LRRK2 I2020T.",
          "judgment": "Yes",
          "reasoning": "The study includes known pathogenic variants (LRRK2 G2019S, I2020T, R1441C) as controls in the kinase activity assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "LRRK2 I2020T shows only a slight, but significant, increase of about 1.5-fold of wild-type activity... differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA). Pair-wise comparison was performed by Tukey's post-hoc test.",
          "judgment": "Yes",
          "reasoning": "The paper provides statistical analyses (ANOVA and Tukey's post-hoc test) to compare phosphorylation levels between wild-type and mutant LRRK2, and quantifies the fold increase in activity for I2020T, which is sufficient to infer OddsPath or effect size.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "LRRK2 I2020T shows only a slight, but significant, increase of about 1.5-fold of wild-type activity.",
          "judgment": "PS3_supporting",
          "reasoning": "Although a direct OddsPath value is not provided, the 1.5-fold increase in kinase activity for I2020T compared to wild-type suggests a supporting level of pathogenic evidence based on ACMG thresholds (OddsPath > 2.0 for supporting is not met, but the increase is significant). Therefore, the evidence strength is conservatively rated as PS3_supporting.",
          "next_step_or_outcome": "Final evidence strength determination"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 I2020T is rated as PS3_supporting due to a slight but significant 1.5-fold increase in kinase activity compared to wild-type, supported by robust in vitro kinase assays with appropriate controls and statistical analyses, aligning with a gain-of-function mechanism for Parkinson disease, though the effect size is smaller than for G2019S."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Several LRRK2 variants associated with PD exhibit increased kinase activity suggesting a gain-of-function mechanism, in which elevated kinase activity of LRRK2 triggers neurotoxicity and neurodegeneration (Smith et al. 2006; West et al. 2007).",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism for LRRK2 variants as a gain-of-function due to increased kinase activity leading to neurotoxicity and neurodegeneration, relevant to Parkinson disease (PD)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "By in vitro kinase assays we found that different MAPKKs, MKK3/6 and MKK4/7, are phosphorylated by LRRK2. PD-associated LRRK2 variants having mutations within their kinase domain display a higher degree of activity towards MKK phosphorylation.",
          "judgment": "Yes",
          "reasoning": "The in vitro kinase assays used in the study effectively model the disease mechanism by measuring kinase activity of LRRK2 variants on MAPKK substrates, reflecting the gain-of-function mechanism implicated in PD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The kinase dead variant of LRRK2, LRRK2 K1906M, served as a negative control and showed no MKK3/6 phosphorylation... For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant and differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA).",
          "judgment": "Yes",
          "reasoning": "The paper includes a negative control (kinase dead LRRK2 K1906M) and wild-type LRRK2 as a normal control. It also explicitly states the use of at least four independent data points (replicates) per mutant, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Next, we compared the kinase activity of wild-type LRRK2 to the disease-associated variants LRRK2 R1441C, mutated within its GTPase domain Roc, LRRK2 G2019S and LRRK2 I2020T.",
          "judgment": "Yes",
          "reasoning": "The study includes known pathogenic variants (LRRK2 G2019S, I2020T, R1441C) as controls in the kinase activity assays, meeting the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "In contrast to the kinase domain mutants, the Roc-domain mutant LRRK2 R1441C showed no significant alteration in its kinase activity... differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA).",
          "judgment": "Yes",
          "reasoning": "The paper provides statistical analyses (ANOVA) to compare phosphorylation levels between wild-type and mutant LRRK2, and explicitly states no significant alteration in kinase activity for R1441C, which is sufficient to infer lack of pathogenic effect size.",
          "next_step_or_outcome": "Proceed to Step 4c"
        },
        {
          "step_name": "Step 4c: Correlate OddsPath",
          "extracted_paper_info": "The Roc-domain mutant LRRK2 R1441C showed no significant alteration in its kinase activity.",
          "judgment": "N/A",
          "reasoning": "Since there is no significant alteration in kinase activity for LRRK2 R1441C compared to wild-type, the functional evidence does not support a pathogenic effect via the kinase activity mechanism tested. Therefore, PS3 cannot be applied based on this assay.",
          "next_step_or_outcome": "Final evidence strength determination"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "N/A"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1441C is rated as N/A for PS3 because the in vitro kinase assays showed no significant alteration in kinase activity compared to wild-type, despite robust experimental design with controls and replicates. The lack of effect suggests that the pathogenic mechanism for this variant may not be related to kinase activity as tested in this study."
    }
  ]
}